title: Effects of long chain omega-3 fatty acids on metalloproteinases and their inhibitors in combined dyslipidemia patients.
abstract: We evaluate the effect of a standardized dietary supplementation with omega-3 polyunsaturated fatty acids (n-3 PUFAs) on the level of some markers of vascular remodeling in patients with combined dyslipidemia. Three hundred and thirty-three patients received placebo or n-3 PUFAs for 6 months. We evaluated body mass index, glycemic profile, blood pressure, lipid profile, lipoprotein(a), plasminogen activator inhibitor-1, homocysteine, fibrinogen, high-sensitivity C reactive protein, ADP, MMP-2 and MMP-9, and tissue inhibitors of metalloproteinase-1 and -2. A significant increase of high-density lipoprotein-cholesterol, and a significant decrease of triglycerides were present after 3 and 6 months with n-3 PUFAs intake. A significant plasminogen activator inhibitor-1, fibrinogen and high-sensitivity C reactive protein decrease was obtained after 3 and 6 months and a significant ADP increase was observed after 3 and 6 months of n-3 PUFAs. A significant MMP-2, MMP-9, tissue inhibitors of metalloproteinase-1 and tissue inhibitors of metalloproteinase-2 decrease was obtained after 6 months compared to the baseline value with n-3 PUFAs intake. n-3 PUFAs give a better lipid profile and a better improvement of coagulation, fibrinolytic and inflammatory parameters than placebo. Furthermore, lowers levels of MMP-2, MMP-9 and their tissue inhibitors are obtained with n-3 PUFAs compared to placebo.
authors.affiliation: University of Pavia, Department of Internal Medicine and Therapeutics, P.le C. Golgi, 2 - 27100, Pavia, Italy. giuseppe.derosa@unipv.it
authors.forename: G
authors.initials: G
authors.lastname: Derosa
authors.forename: P
authors.initials: P
authors.lastname: Maffioli
authors.forename: A
authors.initials: A
authors.lastname: D'Angelo
authors.forename: S A T
authors.initials: SA
authors.lastname: Salvadeo
authors.forename: I
authors.initials: I
authors.lastname: Ferrari
authors.forename: E
authors.initials: E
authors.lastname: Fogari
authors.forename: A
authors.initials: A
authors.lastname: Gravina
authors.forename: R
authors.initials: R
authors.lastname: Mereu
authors.forename: S
authors.initials: S
authors.lastname: Randazzo
authors.forename: A F G
authors.initials: AF
authors.lastname: Cicero
mesh_terms: D016022:Case-Control Studies; D050171:Dyslipidemias / Q000188:drug therapy*; D015525:Fatty Acids, Omega-3 / Q000627:therapeutic use*; D005260:Female; D005342:Fibrinolysis; D006801:Humans; D008297:Male; D045726:Metalloproteases / Q000037:antagonists & inhibitors / Q000378:metabolism*; D010919:Placebos; D011480:Protease Inhibitors / Q000627:therapeutic use*
chemical_list: D015525:Fatty Acids, Omega-3; D010919:Placebos; D011480:Protease Inhibitors; D045726:Metalloproteases